Abstract CT279: DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas
Year: 2024
Type: conference-abstract
Source: Cancer Research
Institutions: Universitat de València, Hospital Clínico Universitario de Valencia, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, German Center for Lung Research, LungenClinic Grosshansdorf, Boehringer Ingelheim (China), Boehringer Ingelheim (Germany), University of California, San Francisco, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4393989542